Oncogenic and Tumor Suppressor Genes Expression in Myeloproliferative Neoplasms: The Hidden Side of a Complex Pathology

Overview

Journal J Clin Lab Anal

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
Pathology

Date 2022 Feb 17

PMID 35176183

Authors

Elham Abedi

Mehran Karimi

Ramin Yaghobi

Hamid Mohammadi

Sezaneh Haghpanah

Mohamad Moghadam

Elahe Bayat

Alireza Rezvani

Mani Ramzi

Affiliations

Soon will be listed here.

Abstract

Background: The present study aimed to explore the changes in the expressions of six tumor-related genes in myeloproliferative neoplasms (MPNs). The study population included 130 patients with MPNs (52 with chronic myeloid leukemia (CML), 49 with essential thrombocythemia (ET), 20 with polycythemia vera (PV), and 9 with primary myelofibrosis (PMF)) and 51 healthy individuals.

Methods: The expression profiling of six genes (ADAMTS18, CMTM5, CDKN2B, DCC, FHIT, and WNT5B) in the peripheral blood granulocyte cells was explored by real-time quantitative reverse transcription polymerase chain reaction.

Results: The patients with MPNs showed significant downregulation of CMTM5 (EFC = 0.66) and DCC (EFC = 0.65) genes in contrast to a non-significant upregulation of ADAMTS18, CDKN2B, FHIT, and WNT5B genes. Downregulation of DCC was consistent in all subtypes of MPN (EFC range: 0.591-0.860). However, CMTM5 had a 1.22-fold upregulation in PMF in contrast to downregulation in other MPN subtypes (EFC range: 0.599-0.775). The results revealed a significant downregulation in CMTM5 and DCC at below 60-years of age. Furthermore, female patients showed a clear-cut downregulation in both CMTM5 and DCC (EFC DCC: 0.436 and CMTM5: 0.570), while male patients presented a less prominent downregulation with a borderline p-value only in DCC (EFC: 0.69; p = 0.05).

Conclusions: Chronic myeloid leukemia cases showed a significant upregulation of WNT5B, as a known oncogenesis gene. Two tumor suppressor genes, namely DCC and CMTM5, were downregulated in the patients with MPNs, especially in females and patients below 60 years of age.

Citing Articles

Oncogenic and tumor suppressor genes expression in myeloproliferative neoplasms: The hidden side of a complex pathology.

Abedi E, Karimi M, Yaghobi R, Mohammadi H, Haghpanah S, Moghadam M J Clin Lab Anal. 2022; 36(4):e24289.

PMID: 35176183 PMC: 8993601. DOI: 10.1002/jcla.24289.

References

Shao L, Guo X, Plate M, Li T, Wang Y, Ma D . CMTM5-v1 induces apoptosis in cervical carcinoma cells. Biochem Biophys Res Commun. 2009; 379(4):866-71. DOI: 10.1016/j.bbrc.2008.12.126. View

Gaman M, Cozma M, Dobrica E, Cretoiu S, Gaman A, Diaconu C . Liquid Biopsy and Potential Liquid Biopsy-Based Biomarkers in Philadelphia-Negative Classical Myeloproliferative Neoplasms: A Systematic Review. Life (Basel). 2021; 11(7). PMC: 8304270. DOI: 10.3390/life11070677. View

Barbui T, Thiele J, Gisslinger H, Kvasnicka H, Vannucchi A, Guglielmelli P . The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018; 8(2):15. PMC: 5807384. DOI: 10.1038/s41408-018-0054-y. View

Jiang H, Wang J, Li H, Peng J, Gao X, Chen F . Influence of the DCC gene on proliferation and carcinoembryonic antigen expression in the human colorectal cancer cell line SW1116. Genet Mol Res. 2015; 14(3):10273-80. DOI: 10.4238/2015.August.28.12. View

Ogun Sercan H, Pehlivan M, Simsek O, Ates H, Sercan Z . Induction of apoptosis increases expression of non-canonical WNT genes in myeloid leukemia cell lines. Oncol Rep. 2007; 18(6):1563-9. View

Lin C, Ho C, Tamamyan G, Yang S, Peng C, Chang J . Validating the Sensitivity of High-Resolution Melting Analysis for JAK2 V617F Mutation in the Clinical Setting. J Clin Lab Anal. 2016; 30(6):838-844. PMC: 6807203. DOI: 10.1002/jcla.21945. View

Kim H, Kitano Y, Mori M, Takano T, Harbaugh T, Mizutani K . The novel secreted factor MIG-18 acts with MIG-17/ADAMTS to control cell migration in Caenorhabditis elegans. Genetics. 2013; 196(2):471-9. PMC: 3914620. DOI: 10.1534/genetics.113.157685. View

Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-405. DOI: 10.1182/blood-2016-03-643544. View

Sefrioui D, Vermeulin T, Blanchard F, Chapusot C, Beaussire L, Armengol-Debeir L . Copy number variations in DCC/18q and ERBB2/17q are associated with disease-free survival in microsatellite stable colon cancer. Int J Cancer. 2016; 140(7):1653-1661. DOI: 10.1002/ijc.30584. View

10.

Niu J, Li H, Zhang Y, Li J, Xie M, Li L . Aberrant expression of CKLF-like MARVEL transmembrane member 5 (CMTM5) by promoter methylation in myeloid leukemia. Leuk Res. 2010; 35(6):771-6. DOI: 10.1016/j.leukres.2010.11.023. View

11.

Chen H, Wei Z, Sun J, Bhattacharya A, Savage D, Serda R . A recellularized human colon model identifies cancer driver genes. Nat Biotechnol. 2016; 34(8):845-51. PMC: 4980997. DOI: 10.1038/nbt.3586. View

12.

Arakawa H . Netrin-1 and its receptors in tumorigenesis. Nat Rev Cancer. 2004; 4(12):978-87. DOI: 10.1038/nrc1504. View

13.

Rampal R, Al-Shahrour F, Abdel-Wahab O, Patel J, Brunel J, Mermel C . Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014; 123(22):e123-33. PMC: 4041169. DOI: 10.1182/blood-2014-02-554634. View

14.

Inokuchi K, Miyake K, Takahashi H, Dan K, Nomura T . DCC protein expression in hematopoietic cell populations and its relation to leukemogenesis. J Clin Invest. 1996; 97(3):852-7. PMC: 507125. DOI: 10.1172/JCI118486. View

15.

Inokuchi K, Yamaguchi H, Hanawa H, Tanosaki S, Nakamura K, Tarusawa M . Loss of DCC gene expression is of prognostic importance in acute myelogenous leukemia. Clin Cancer Res. 2002; 8(6):1882-8. View

16.

Wang S, Chang J, Hsiao J, Yen Y, Jiang S, Liu S . Tumour cell-derived WNT5B modulates in vitro lymphangiogenesis via induction of partial endothelial-mesenchymal transition of lymphatic endothelial cells. Oncogene. 2016; 36(11):1503-1515. DOI: 10.1038/onc.2016.317. View

17.

Harada T, Yamamoto H, Kishida S, Kishida M, Awada C, Takao T . Wnt5b-associated exosomes promote cancer cell migration and proliferation. Cancer Sci. 2016; 108(1):42-52. PMC: 5276837. DOI: 10.1111/cas.13109. View

18.

Miyake K, Inokuchi K, Nomura T . Expression of the DCC gene in human hematological malignancies. Leuk Lymphoma. 1994; 16(1-2):13-8. DOI: 10.3109/10428199409114135. View

19.

Lu D, Zhao Y, Tawatao R, Cottam H, Sen M, Leoni L . Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2004; 101(9):3118-23. PMC: 365753. DOI: 10.1073/pnas.0308648100. View

20.

Nguyen-Khac F, Lesty C, Eclache V, Couronne L, Kosmider O, Andrieux J . Chromosomal abnormalities in transformed Ph-negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations. Genes Chromosomes Cancer. 2010; 49(10):919-27. DOI: 10.1002/gcc.20802. View